Sweden · Research startup
Sweden · AnaCardio
AnaCardio is a clinical-stage biopharmaceutical company based in Solna, Sweden, focused on developing innovative treatments for heart failure.
Funding reportedLast round: Series A
About AnaCardio
AnaCardio is a clinical-stage biopharmaceutical company based in Solna, Sweden, focused on developing innovative treatments for heart failure.
Founded in 2017, the company emerged from research at Karolinska Institutet that revealed a unique mechanism to enhance heart muscle contractility. AnaCardio employs around 11 people and operates within the Healthcare & Life Sciences sector. The company's lead product, AC01, is a first-in-class oral medication designed to improve heart muscle function without causing common side effects associated with traditional therapies. AC01 is currently in Phase 1b/2a clinical development, targeting patients with heart failure and reduced ejection fraction (HFrEF). AnaCardio aims to enhance cardiac output and quality of life for these patients while reducing hospitalization and mortality risks. The company has successfully raised over $35 million in funding, with significant backing from investors like Novo Holdings and Sound Bioventures.
What company datasets say AnaCardio raised
Funding, as reported
On 4 portfolio pages
Investors who name them
Each firm lists AnaCardio on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
biotechnology researchb2b
Built with from their website
Microsoft ExchangeMicrosoft 365OutlookMicrosoft 365 Apps & ServicesMicrosoft Email ProvidersMicrosoft Exchange Online
- Sector
- Research
- Industry code
- NAICS 541714, 325412, SIC 8731, 2834
- Region
- Vaestra Goetaland County
- Revenue
- 2M a year, as listed
Research in Sweden
Startups like it
Is this your company?
Add your raise, your deck and your story, and put AnaCardio in front of investors. Or tell us what we have wrong.